 |
|
|
| |
HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in HBeAg-Positive and Negative Virally SuppressedPatientsWith Hepatitis B
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Poster pdf attached to see better all the slides
Kosh Agarwal1, Ed Gane2, Wendy Cheng3, William Sievert4, Stuart Roberts5, Sang Hoon Ahn6, Yoon Jun Kim7, Adrian Streinu-Cercel8, Jill Denning9, William Symonds9, Patricia Mendez9
1Institute of Liver Studies,King's College Hospital, United Kingdom; 2Auckland Clinical Studies Limited, Auckland, New Zealand; 3Royal Perth Hospital and Linear Research, Perth, Australia; 4Monash Health and Monash University, Melbourne, Australia; 5The Alfred, Melbourne, Australia; 6Yonsei University College of Medicine, Seoul, South Korea; 7Seoul National University College of Medicine, Seoul, South Korea; 8Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. MateiBals", Bucharest, Romania; 9Arbutus Biopharma Corporation, Burnaby, Canada.
|
| |
|
|
|
|
|
